Molecular markers to identify patients at risk for recurrence after primary treatment for prostate cancer

Urology

Volumn 62, Issue SUPPL. 1, 2003, Pages 19-35

  Kumar Sinha, Chandan ^a   Chinnaiyan, Arul M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ANNEXIN; BIOLOGICAL MARKER; CAVEOLIN 1; CONNECTIVE TISSUE GROWTH FACTOR; CYCLIN DEPENDENT KINASE 1; ENDOPEPTIDASE LA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FATTY ACID SYNTHASE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; KALLIKREIN; KI 67 ANTIGEN; MOLECULAR MARKER; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; PROSTATE STEM CELL ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN KINASE B; PROTEIN P27; PROTEOME; S PHASE KINASE ASSOCIATED PROTEIN 2; SCATTER FACTOR RECEPTOR; THYMOSIN; THYMOSIN BETA 15; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UVOMORULIN; PLASMA PROTEIN; TUMOR MARKER; TUMOR PROTEIN;

APOPTOSIS; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CANCER THERAPY; CELL PROLIFERATION; CHROMOSOME 8Q; GENETIC ANALYSIS; HUMAN; NOMOGRAM; PARAMETER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEOMICS; REVIEW; TREATMENT OUTCOME; ADENOCARCINOMA; ALGORITHM; BLOOD; CELL DIVISION; CHEMISTRY; CHROMOSOME 8; DISEASE COURSE; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETICS; MALE; METASTASIS; PROSTATE TUMOR; TUMOR RECURRENCE; ULTRASTRUCTURE;

ADENOCARCINOMA; ALGORITHMS; APOPTOSIS; BLOOD PROTEINS; CELL DIVISION; CHROMOSOMES, HUMAN, PAIR 8; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROSTATIC NEOPLASMS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 1842862680     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2003.10.007     Document Type: Article

References (201)

1. Abate-Shen C, and Shen MM: Molecular genetics of prostate cancer. Genes Dev 14: 2410-2434, 2000.
2. Catalona WJ, Richie JP, Ahmann FR, et al: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 51: 1283-1290, 1994.
3. Jacobsen SJ, Katusic SK, Bergstralh EJ, et al: Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA 274: 1445-1449, 1995.
4. Epstein JI, and Potter SR: The pathological interpretation and significance of prostate needle biopsy findings: implications and current controversies. J Urol 166: 402-410, 2001.
5. Albertsen PC, Hanley JA, Gleason DF, et al: Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280: 975-980, 1998.
6. Day JC: Population Projections of the United States by Age, Sex, and Hispanic Origin: 1995-2050. Washington, DC, US Bureau of Census, 1996 pp 25-1130.
7. Ohori M, Graefen M, Hwang YM, et al: Features of cancer in systematic biopsies improve the prediction of clinical indolent prostate cancer in patients undergoing radical prostatectomy [abstract]. J Urol 165: A1454, 2001.
8. Kattan MW: Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 95: 634-635, 2003.
9. Ross PL, Scardino PT, and Kattan MW: A catalog of prostate cancer nomograms. J Urol 165: 1562-1568, 2001.
10. Ross PL, Gerigk C, Gonen M, et al: Comparisons of nomograms and urologists' predictions in prostate cancer. Semin Urol Oncol 20: 82-88, 2002.
11. Partin AW, Piantadosi S, Sanda MG, et al: Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 45: 831-838, 1995.
12. Blute ML, Bergstralh EJ, Iocca A, et al: Use of Gleason score: prostate-specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 165: 119-125, 2001.
13. Kattan MW, Wheeler TM, and Scardino PT: Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 17: 1499-1507, 1999.
14. Kattan MW, Potters L, Blasko JC, et al: Pretreatment nomograin for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology 58: 393-399, 2001.
15. Kattan MW, Eastham JA, Stapleton AM, et al: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90: 766-771, 1998.
16. Young RA: Biomedical discovery with DNA arrays. Cell 102: 9-15, 2000.
17. Dhanasekaran SM, Barrette TR, Ghosh D, et al: Delineation of prognostic biomarkers in prostate cancer. Nature 412: 822-826, 2001.
18. Luo JH, Yu YP, Cieply K, et al: Gene expression analysis of prostate cancers. Mol Carcinog 33: 25-35, 2002.
19. Welsh JB, Sapinoso LM, Su AI, et al: Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 61: 5974-5978, 2001.
20. Magee JA, Araki T, Patil S, et al: Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 61: 5692-5696, 2001.
21. Luo J, Duggan DJ, Chen Y, et al: Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res 61: 4683-4688, 2001.
22. Ernst T, Hergenhahn M, Kenzelmann M, et al: Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. Am J Pathol 160: 2169-2180, 2002.
23. Singh D, Febbo PG, Ross K, et al: Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1: 203-209, 2002.
24. Rhodes DR, Barrette TR, Rubin MA, et al: Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 62: 4427-4433, 2002.
25. Tsuchiya N, Kondo Y, Takahashi A, et al: Mapping and gene expression profile of the minimally overrepresented 8q24 region in prostate cancer. Am J Pathol 160: 1799-1806, 2002.
26. Tsuchiya N, Slezak JM, Lieber MM, et al: Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer. Genes Chromosomes Cancer 34: 363-371, 2002.
27. Sato K, Qian J, Slezak JM, et al: Clinical significance of alterations of chromosome 8 in high-grade, advanced, non-metastatic prostate carcinoma. J Natl Cancer Inst 91: 1574-1580, 1999.
28. Rubin MA, Zhou M, Dhanasekaran SM, et al: α-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 287: 1662-1670, 2002.
29. Luo J, Zha S, Gage WR, et al: Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 62: 2220-2226, 2002.
30. Kuefer R, Varambally S, Zhou M, et al: α-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation. Am J Pathol 161: 841-848, 2002.
31. Zheng SL, Chang BL, Faith DA, et al: Sequence variants of alpha-methylacyl-CoA racemase are associated with prostate cancer risk. Cancer Res 62: 6485-6488, 2002.
32. Srivastava M, Bubendorf L, Srikantan V, et al: ANX7, a candidate tumor suppressor gene for prostate cancer. Proc Natl Acad Sci U S A 98: 4575-4580, 2001.
33. Xin W, Rhodes DR, Ingold C, et al: Dysregulation of the annexin family protein family is associated with prostate cancer progression. Am J Pathol 162: 255-261, 2003.
34. Bubendorf L, Sauter G, Moch H, et al: Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am J Pathol 148: 1557-1565, 1996.
35. Scherr DS, Vaughan ED Jr, Wei, J, et al: BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. J Urol 162: 12-16; discussion, 16-17, 1999.
36. Pollack A, Cowen D, Troncoso P, et al: Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x. Cancer 97: 1630-1638, 2003.
37. Keshgegian AA, Johnston E, and Cnaan A: Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am J Clin Pathol 110: 443-449, 1998.
38. Mackey TJ, Borkowski A, Amin P, et al: bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology 52: 1085-1090, 1998.
39. Yang G, Truong LD, Wheeler TM, et al: Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res 59: 5719-5723, 1999.
40. Li L, Yang G, Ebara S, et al: Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res 61: 4386-4392, 2001.
41. Mouraviev V, Li L, Tahir SA, et al: The role of caveolin-1 in androgen insensitive prostate cancer. J Urol 168: 1589-1596, 2002.
42. Kallakury BV, Sheehan CE, Ambros RA, et al: The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma. Cancer 80: 753-763, 1997.
43. Kallakury BV, Sheehan CE, Rhee SJ, et al: The prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocarcinoma: a comparison with cyclins A and B1, Ki-67, proliferating cell nuclear antigen, and p34cdc2. Cancer 85: 1569-1576, 1999.
44. Brewster SF, Oxley JD, Trivella M, et al: Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. J Urol 161: 1238-1243, 1999.
45. Umbas R, Isaacs WB, Bringuier PP, et al: Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 54: 3929-3933, 1994.
46. Kallakury BV, Sheehan CE, and Ross JS: Co-down-regulation of cell adhesion proteins alpha- and beta-catenins, p120CTN, E-cadherin, and CD44 in prostatic adenocarcinomas. Hum Pathol 32: 849-855, 2001.
47. Rhodes DR, Sanda MG, Otte AP, et al: Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 95: 661-668, 2003.
48. Varambally S, Dhanasekaran SM, Zhou M, et al: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-629, 2002.
49. Sellers WR, and Loda M: The EZH2 polycomb transcriptional repressor: a marker or mover of metastatic prostate cancer? Cancer Cell 2: 349-350, 2002.
50. Epstein JI, Carmichael M, and Partin AW: OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. Urology 45: 81-86, 1995.
51. Shurbaji MS, Kalbfleisch JH, and Thurmond TS: Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer. Hum Pathol 27: 917-921, 1996.
52. Myers RB, Oelschlager DK, Weiss HL, et al: Fatty acid synthase: an early molecular marker of progression of prostatic adenocarcinoma to androgen independence. J Urol 165: 1027-1032, 2001.
53. Swinnen JV, Roskams T, Joniau S, et al: Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer 98: 19-22, 2002.
54. Stamey TA, Warrington JA, Caldwell MC, et al: Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared with benign prostatic hyperplasia. J Urol 166: 2171-2177, 2001.
55. Srikantan V, Valladares M, Rhim JS, et al: HEPSIN inhibits cell growth/invasion in prostate cancer cells. Cancer Res 62: 6812-6816, 2002.
56. Morote J, de Torres I, Caceres C, et al: Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer. Int J Cancer 84: 421-425, 1999.
57. Signoretti S, Montironi R, Manola J, et al: Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 92: 1918-1925, 2000.
58. Reese DM, Small EJ, Magrane G, et al: HER2 protein expression and gene amplification in androgen-independent prostate cancer. Am J Clin Pathol 116: 234-239, 2001.
59. Lara PN Jr, Meyers FJ, Gray CR, et al: HER-2/neu is overexpressed infrequently in patients with prostate carcinoma: results from the California Cancer Consortium Screening Trial. Cancer 94: 2584-2589, 2002.
60. Sanchez KM, Sweeney CJ, Mass R, et al: Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a request for a standardized, organ specific methodology. Cancer 95: 1650-1655, 2002.
61. Shariat SF, Lamb DJ, Kattan MW, et al: Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol 20: 833-841, 2002.
62. Miyata Y, Sakai H, Hayashi T, et al: Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer. Prostate 54: 125-132, 2003.
63. Thrasher JB, Tennant MK, Twomey PA, et al: Immunohistochemical localization of insulin-like growth factor binding proteins 2 and 3 in prostate tissue: clinical correlations. J Urol 155: 999-1003, 1996.
64. Giri D, Ozen M, and Ittmann M: Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 159: 2159-2165, 2001.
65. Drachenberg DE, Elgamal AA, Rowbotham R, et al: Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 41: 127-133, 1999.
66. Nakashima J, Tachibana M, Horiguchi Y, et al: Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 6: 2702-2706, 2000.
67. Shariat SF, Andrews B, Kattan MW, et al: Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 58: 1008-1015, 2001.
68. Haese A, Becker C, Noldus J, et al: Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer. J Urol 163: 1491-1497, 2000.
69. Haese A, Graefen M, Steuber T, et al: Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. Prostate 49: 101-109, 2001.
70. Recker F, Kwiatkowski MK, Piironen T, et al: Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen. Urology 55: 481-485, 2000.
71. Bubendorf L, Sauter G, Moch H, et al: Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 178: 437-441, 1996.
72. Bubendorf L, Tapia C, Gasser TC, et al: Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum Pathol 29: 949-954, 1998.
73. Khoo VS, Pollack A, Cowen D, et al: Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy. Prostate 41: 166-172, 1999.
74. Watanabe M, Fukutome K, Kato H, et al: Progression-linked overexpression of c-Met in prostatic intraepithelial neoplasia and latent as well as clinical prostate cancers. Cancer Lett 141: 173-178, 1999.
75. Knudsen BS, Ginyrek GA, Inra J, et al: High expression of the Met receptor in prostate cancer metastasis to bone. Urology 60: 1113-1117, 2002.
76. van Leenders G, van Balken B, Aalders T, et al: Intermediate cells in normal and malignant prostate epithelium express c-MET: implications for prostate cancer invasion. Prostate 51: 98-107, 2002.
77. Yang RM, Naitoh J, Murphy M, et al: Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 159: 941-945, 1998.
78. Freedland SJ, deGregorio F, Sacoolidge JC, et al: Preoperative p27 status is an independent predictor of prostate specific antigen failure following radical prostatectomy. J Urol 169: 1325-1330, 2003.
79. Vis AN, Noordzij MA, Fitoz K, et al: Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. J Urol 164: 2156-2161, 2000.
80. Halvorsen OJ, Haukaas SA, and Akslen LA: Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin Cancer Res 9: 1474-1479, 2003.
81. Malik SN, Brattain M, Ghosh PM, et al: Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 8: 1168-1171, 2002.
82. Reiter RE, Gu Z, Watabe T, et al: Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A 95: 1735-1740, 1998.
83. Jalkut MW, and Reiter RE: Role of prostate stem cell antigen in prostate cancer research. Curr Opin Urol 12: 401-406, 2002.
84. Reiter RE, Sato I, Thomas G, et al: Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. Genes Chromosomes Cancer 27: 95-103, 2000.
85. Gu Z, Thomas G, Yamashiro J, et al: Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 19: 1288-1296, 2000.
86. McMenamin ME, Soung P, Perera S, et al: Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 59: 4291-4296, 1999.
87. Whang YE, Wu X, Suzuki H, et al: Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A 95: 5246-5250, 1998.
88. Ben-Izhak O, Lahav-Baratz S, Meretyk S, et al: Inverse relationship between Skp2 ubiquitin ligase and the cyclin dependent kinase inhibitor p27Kip1 in prostate cancer. J Urol 170: 241-245, 2003.
89. Yang G, Ayala G, Marzo AD, et al: Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res 8: 3419-3426, 2002.
90. Perry KT, Anthony CT, and Steiner MS: Immunohistochemical localization of TGF beta 1, TGF beta 2, and TGF beta 3 in normal and malignant human prostate. Prostate 33: 133-140, 1997.
91. Perry KT, Anthony CT, Case T, et al: Transforming growth factor beta as a clinical biomarker for prostate cancer. Urology 49: 151-155, 1997.
92. Wolff JM, Fandel TH, Borchers H, et al: Serum concentrations of transforming growth factor-beta 1 in patients with benign and malignant prostatic diseases. Anticancer Res 19: 2657-2659, 1999.
93. Adler HL, McCurdy MA, Rattan MW, et al: Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma. J Urol 161: 182-187, 1999.
94. 1) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol 19: 2856-2864, 2001.
95. Bao L, Loda M, Janmey PA, et al: Thymosin β15: a novel regulator of tumor cell motility upregulated in metastatic prostate cancer. Nat Med 2: 1322-1328, 1996.
96. Bao L, Loda M, and Zetter BR: Thymosin β15 expression in tumor cell lines with varying metastatic potential. Clin Exp Metastasis 16: 227-233, 1998.
97. Chakravatri A, Zehr EM, Zietman AL, et al: Thymosin β-15 predicts for distant failure in patients with clinically localized prostate cancer: results from a pilot study. Urology 55: 635-638, 2000.
98. Wu HC, Lin CC, Chen WC, et al: Osteocalcin gene HindIII C/T polymorphism is a biomarker for prostate cancer and responsiveness to hormone therapy. Eur Urol 43: 197-200, 2003.
99. Kristiansen G, Pilarsky C, Wissmann C, et al: ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate 54: 34-43, 2003.
100. Jeronimo C, Henrique R, Campos PF, et al: Endothelin B receptor gene hypermethylation in prostate adenocarcinoma. J Clin Pathol 56: 52-55, 2003.
101. Yashi M, Muraishi O, Kobayashi Y, et al: Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients. Prostate 51: 84-97, 2002.
102. Xu J, Zheng SL, Komiya A, et al: Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 32: 321-325, 2002.
103. Wikstrom P, Lissbrant IF, Stattin P, et al: Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 51: 268-275, 2002.
104. Liu Y, Jovanovic B, Pins M, et al: Over expression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion. Oncogene 21: 8272-8281, 2002.
105. Wang Q, Sharma D, Ren Y, et al: A coregulatory role for the TRAP-mediator complex in androgen receptor-mediated gene expression. J Biol Chem 277: 42852-42858, 2002.
106. Velasco A, Hewitt SM, Albert PS, et al: Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence. Cancer 94: 690-699, 2002.
107. Shibata A, Garcia MI, Cheng I, et al: Polymorphisms in the androgen receptor and type II 5 alpha-reductase genes and prostate cancer prognosis. Prostate 52: 269-278, 2002.
108. Schatzl G, Madersbacher S, Gsur A, et al: Association of polymorphisms within androgen receptor, 5α-reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men. Prostate 52: 130-138, 2002.
109. Yu L, Blackburn GL, and Zhou JR: Genistein and daid-zein downregulate prostate androgen-regulated transcript-1 (PART-1) gene expression induced by dihydrotestosterone in human prostate LNCaP cancer cells. J Nutr 133: 389-392, 2003.
110. Sidiropoulos M, Chang A, Jung K, et al: Expression and regulation of prostate androgen regulated transcript-1 (PART-1) and identification of differential expression in prostatic cancer. Br J Cancer 85: 393-397, 2001.
111. Rao DS, Hyun TS, Kumar PD, et al: Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival. J Clin Invest 110: 351-360, 2002.
112. Noss KR, Wolfe SA, and Grimes SR: Upregulation of prostate specific membrane antigen/folate hydrolase transcription by an enhancer. Gene 285: 247-256, 2002.
113. Burger MJ, Tebay MA, Keith PA, et al: Expression analysis of delta-catenin and prostate-specific membrane antigen: their potential as diagnostic markers for prostate cancer. Int J Cancer 100: 228-237, 2002.
114. Adsan O, Cecchini MG, Bisoffi M, et al: Can the reverse transcriptase-polymerase chain reaction for prostate specific antigen and prostate specific membrane antigen improve staging and predict biochemical recurrence? BJU Int 90: 579-585, 2002.
115. Meyer-Siegler KL, Bellino MA, and Tannenbaum M: Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma. Cancer 94: 1449-1456, 2002.
116. Kosari F, Asmann YW, Cheville JC, et al: Cysteine-rich secretory protein-3: a potential biomarker for prostate cancer. Cancer Epidemiol Biomarkers Prev 11: 1419-1426, 2002.
117. Ide H, Seligson DB, Memarzadeh S, et al: Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progression. Proc Natl Acad Sci U S A 99: 14404-14409, 2002.
118. Deyoung MP, Scheurle D, Damania H, et al: Down's syndrome-associated single minded gene as a novel tumor marker. Anticancer Res 22: 3149-3157, 2002.
119. de Kok JB, Verhaegh GW, Roelofs RW, et al: DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 62: 2695-2698, 2002.
120. Casey G, Neville PJ, Plummer SJ, et al: RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 32: 581-583, 2002.
121. Cangul H, Salnikow K, Yee H, et al: Enhanced overexpression of an HIF-1/hypoxia-related protein in cancer cells. Environ Health Perspect 110(suppl 5): 783-788, 2002.
122. Bochum S, Paiss T, Vogel W, et al: Confirmation of the prostate cancer susceptibility locus HPCX in a set of 104 German prostate cancer families. Prostate 52: 12-19, 2002.
123. Xu J, Kalos M, Stolk JA, et al: Identification and characterization of prostein, a novel prostate-specific protein. Cancer Res 61: 1563-1568, 2001.
124. Tsavaler L, Shapero MH, Morkowski S, et al: Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res 61: 3760-3769, 2001.
125. Gronberg H, Ahman AK, Emanuelsson M, et al: BRCA2 mutation in a family with hereditary prostate cancer. Genes Chromosomes Cancer 30: 299-301, 2001.
126. Verkaik NS, van Steenbrugge GJ, van Weerden WM, et al: Silencing of CD44 expression in prostate cancer by hypermethylation of the CD44 promoter region. Lab Invest 80: 1291-1298, 2000.
127. Aaltomaa S, Lipponen P, Viitanen J, et al: Prognostic value of CD44 standard, variant isoforms 3 and 6 and α-catenin expression in local prostate cancer treated by radical prostatectomy. Eur Urol 38: 555-562, 2000.
128. Verkaik NS, Trapman J, Romijn JC, et al: Down-regulation of CD44 expression in human prostatic carcinoma cell lines is correlated with DNA hypermethylation. Int J Cancer 80: 439-443, 1999.
129. Gsur A, Bernhofer G, Hinteregger S, et al: A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int J Cancer 87: 434-437, 2000.
130. Birckbichler PJ, Bonner RB, Hurst RE, et al: Loss of tissue transglutaminase as a biomarker for prostate adenocarcinoma. Cancer 89: 412-423, 2000.
131. Hubert RS, Vivanco I, Chen E, et al: STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci U S A 96: 14523-14528, 1999.
132. Alers JC, Rochat J, Krijtenburg PJ, et al: Identification of genetic markers for prostatic cancer progression. Lab Invest 80: 931-942, 2000.
133. Cher ML, Bova GS, Moore DH, et al: Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 56: 3091-3102, 1996.
134. Qian J, Bostwick DG, Takahashi S, et al: Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res 55: 5408-5414, 1995.
135. Bova GS, and Isaacs WB: Review of allelic loss and gain in prostate cancer. World J Urol 14: 338-346, 1996.
136. Visakorpi T, Kallioniemi AH, Syvanen AC, et al: Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 55: 342-347, 1995.
137. Karan D, Lin MF, Johansson SL, et al: Current status of the molecular genetics of human prostatic adenocarcinomas. Int J Cancer 103: 285-293, 2003.
138. Zitzelsberger H, Engert D, Walch A, et al: Chromosomal changes during development and progression of prostate adenocarcinomas. Br J Cancer 84: 202-208, 2001.
139. Dumur CI, Dechsukhum C, Ware JL, et al: Genome-wide detection of LOH in prostate cancer using human SNP microarray technology. Genomics 81: 260-269, 2003.
140. Nupponen NN, and Visakorpi T: Molecular cytogenetics of prostate cancer. Microsc Res Tech 51: 456-463, 2000.
141. Verma RS, Manikal M, Conte RA, et al: Chromosomal basis of adenocarcinoma of the prostate. Cancer Invest 17: 441-447, 1999.
142. Qian J, Hirasawa K, Bostwick DG, et al: Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression. Mod Pathol 15: 35-44, 2002.
143. Erdamar S, Yang G, Harper JW, et al: Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis. Mod Pathol 12: 751-755, 1999.
144. Borre M, Stausbol-Gron B, Nerstrom B, et al: Immunohistochemical BCL-2 and Ki-67 expression predict survival in prostate cancer patients followed expectantly. Prostate Cancer Prostatic Dis 1: 268-275, 1998.
145. Coffey DS: Prostate cancer metastasis: talking the walk. Nat Med 2: 1305-1306, 1996.
146. Verhoeven G: Androgens and increased lipogenesis in prostate cancer: cell biologic and clinical perspectives [in Dutch]. Verb K Acad Geneeskd Belg 64: 189-195, 2002.
147. Bull JH, Ellison G, Patel A, et al: Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using cDNA microarray. Br J Cancer 84: 1512-1519, 2001.
148. Pisters LL, Troncoso P, Zhau HE, et al: c-met Protooncogene expression in benign and malignant human prostate tissues. J Urol 154: 293-298, 1995.
149. Humphrey PA, Zhu X, Zarnegar R, et al: Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 147: 386-396, 1995.
150. van Leenders GJ, Gage WR, Hicks JL, et al: Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am J Pathol 162: 1529-1537, 2003.
151. Elo JP, and Visakorpi T: Molecular genetics of prostate cancer. Ann Med 33: 130-141, 2001.
152. Giroldi LA, and Schalken JA: Decreased expression of the intercellular adhesion molecule E-cadherin in prostate cancer: biological significance and clinical implications. Cancer Metastasis Rev 12: 29-37, 1993.
153. Umbas R, Schalken JA, Aalders TW, et al: Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 52: 5104-5109, 1992.
154. Dong JT, Rinker-Schaeffer CW, Ichikawa T, et al: Prostate cancer-biology of metastasis and its clinical implications. World J Urol 14: 182-189, 1996.
155. Perlino E, Lovecchio M, Vacca RA, et al: Regulation of mRNA and protein levels of beta 1 integrin variants in human prostate carcinoma. Am J Pathol 157: 1727-1734, 2000.
156. Best CJ, Leiva IM, Chuaqui RF, et al: Molecular differentiation of high- and moderate-grade human prostate cancer by cDNA microarray analysis. Diagn Mol Pathol 12: 63-70, 2003.
157. Buttyan R, Sawczuk IS, Benson MC, et al: Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers. Prostate 11: 327-337, 1987.
158. Weston K: Reassessing the role of C-MYB in tumorigenesis. Oncogene 18: 3034-3038, 1999.
159. Xu J, Stolk JA, Zhang X, et al: Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res 60: 1677-1682, 2000.
160. Jiang Z, Wu CL, Woda BA, et al: P504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy. Am J Surg Pathol 26: 1169-1174, 2002.
161. Yang XJ, Wu CL, Woda BA, et al: Expression of alpha-Methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate. Am J Surg Pathol 26: 921-925, 2002.
162. Zhou M, Jiang Z, and Epstein JI: Expression and diagnostic utility of alpha-methylacyl-CoA-racemase (P504S) in foamy gland and pseudohyperplastic prostate cancer. Am J Surg Pathol 27: 772-778, 2003.
163. Zhou M, Chinnaiyan AM, Kleer CG, et al: Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol 26: 926-931, 2002.
164. Gerke V, and Moss SE: Annexins: from structure to function. Physiol Rev 82: 331-371, 2002.
165. Chetcuti A, Margan SH, Russell P, et al: Loss of annexin II heavy and light chains in prostate cancer and its precursors. Cancer Res 61: 6331-6334, 2001.
166. Paweletz CP, Ornstein DK, Roth MJ, et al: Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res 60: 6293-6297, 2000.
167. Srivastava M, Bubendorf L, Nolan L, et al: ANX7 as a bio-marker in prostate and breast cancer progression. Dis Markers 17: 115-120, 2001.
168. Liu JW, Shen JJ, Tanzillo-Swarts A, et al: Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration. Oncogene 22: 1475-1485, 2003.
169. Zetter BR, and Banyard J: Cancer: the silence of the genes. Nature 419: 572-573, 2002.
170. Chung CH, Bernard PS, and Perou CM: Molecular portraits and the family tree of cancer. Nat Genet 32(suppl): 533-40, 2002.
171. Canto EI, Shariat SF, and Slawin KM: Biochemical staging of prostate cancer. Urol Clin North Am 30: 263-277, 2003.
172. Lowe FC, and Trauzzi SJ: Prostatic acid phosphatase in 1993: its limited clinical utility. Urol Clin North Am 20: 589-595, 1993.
173. Bahnson RR, and Catalona WJ: Adverse implications of acid phosphatase levels in the upper range of normal. J Urol 137: 427-430, 1987.
174. Burnett AL, Chan DW, Brendler CB, et al: The value of serum enzymatic acid phosphatase in the staging of localized prostate cancer. J Urol 148: 1832-1834, 1992.
175. Swindle PW, Kattan MW, and Scardino PT: Markers and meaning of primary treatment failure. Urol Clin North Am 30: 377-401, 2003.
176. Scherr D, Swindle PW, and Scardino PT: National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology 61: 14-24, 2003.
177. Bostwick DG, Qian J, and Schlesinger C: Contemporary pathology of prostate cancer. Urol Clin North Am 30: 181-207, 2003.
178. Haese A, Graefen M, Becker C, et al: The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer. Prostate 54: 181-186, 2003.
179. Diamandis EP, and Yousef GM: Human tissue kallikreins: a family of new cancer biomarkers. Clin Chem 48: 1198-1205, 2002.
180. Yousef GM, and Diamandis EP: Expanded human tissue kallikrein family: a novel panel of cancer biomarkers. Tumour Biol 23: 185-192, 2002.
181. Karazanashvili G, and Abrahamsson PA: Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancer. J Urol 169: 445-457, 2003.
182. Bubendorf L, Kolmer M, Kononen J, et al: Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst 91: 1758-1764, 1999.
183. Chaib H, Cockrell EK, Rubin MA, et al: Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis. Neoplasia 3: 43-52, 2001.
184. Richardsen E, Ukkonen T, Bjornsen T, et al: Overexpression of IGBFB2 is a
185. Parton RG: Caveolae and caveolins. Curr Opin Cell Biol 8: 542-548, 1996.
186. Bangma CH, Nasu Y, Ren C, et al: Metastasis-related genes in prostate cancer. Semin Oncol 26: 422-427, 1999.
187. Thompson TC: Metastasis-related genes in prostate cancer: the role of caveolin-1. Cancer Metastasis Rev 17: 439-442, 1998.
188. Yang G, Truong LD, Timme TL, et al: Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 4: 1873-1880, 1998.
189. Satoh T, Yang G, Egawa S, et al: Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients. Cancer 97: 1225-1233, 2003.
190. Nasu Y, Timme TL, Yang G, et al: Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat Med 4: 1062-1064, 1998.
191. Tahir SA, Yang G, Ebara S, et al: Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 61: 3882-3885, 2001.
192. Akhurst RJ, and Derynck R: TGF-β signaling in cancer: a double-edged sword. Trends Cell Biol 11: S44-S51, 2001.
193. Derynck R, Akhurst RJ, and Balmain A: TGF-β signaling in tumor suppression and cancer progression. Nat Genet 29: 117-129, 2001.
194. Adam BL, Qu Y, Davis JW, et al: Serum protein finger-printing coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 62: 3609-3614, 2002.
195. Petricoin EF 3rd, Ornstein DK, Paweletz CP, et al: Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 94: 1576-1578, 2002.
196. Li J, Zhang Z, Rosenzweig J, et al: Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 48: 1296-1304, 2002.
197. Qu Y, Adam BL, Yasui Y, et al: Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 48: 1835-1843, 2002.
198. Petricoin EF, Ardekani AM, Hitt BA, et al: Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359: 572-577, 2002.
199. Mintz PJ, Kim J, Do KA, et al: Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol 21: 57-63, 2003.
200. Ornstein DK, Gillespie JW, Paweletz CP, et al: Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis 21: 2235-2242, 2000.
201. Diamandis EP: Re: Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 95: 489-490; author reply 490-491, 2003.